|
122 Companies |
|
196 Products |
|
196 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2338 News |
|
| «12...35363738394041424344454647» |
- HPP854 / vTv Therapeutics
Trial termination: Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease (clinicaltrials.gov) - Aug 28, 2012
P1, N=7, Terminated, Sponsor: High Point Pharmaceuticals, LLC.
Recruiting --> Terminated
- HPP854 / vTv Therapeutics
Enrollment change: Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease (clinicaltrials.gov) - Aug 28, 2012
P1, N=7, Terminated, Sponsor: High Point Pharmaceuticals, LLC.
Recruiting --> Terminated N=30 --> 7
- TTP4000 / vTv Therapeutics
Enrollment closed: A Safety Study of TTP4000 in Subjects With Alzheimer's Disease (clinicaltrials.gov) - Aug 28, 2012
P1, N=16, Active, not recruiting, Sponsor: TransTech Pharma
N=30 --> 7 Recruiting --> Active, not recruiting
- | vanutide cridificar (PF-236806) / J&J, Perrigo Company, Pfizer
Trial completion: Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease (clinicaltrials.gov) - Aug 27, 2012
P2a, N=40, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| donepezil / Generic mfg.
Trial completion: CONCERT: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (clinicaltrials.gov) - Aug 26, 2012
P3, N=1003, Completed, Sponsor: Medivation, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Trial completion: CONNECTION: A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease (clinicaltrials.gov) - Aug 26, 2012
P3, N=598, Completed, Sponsor: Medivation, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | bapineuzumab (AAB-001) / Pfizer, J&J, Perrigo Company
Trial termination: RAPID: Retrieval of Patient Information After Discontinuation (clinicaltrials.gov) - Aug 23, 2012
P3b, N=169, Terminated, Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Active, not recruiting --> Completed Enrolling by invitation --> Terminated
- | bapineuzumab (AAB-001) / Pfizer, J&J, Perrigo Company
Trial termination: A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Aug 23, 2012
P3, N=896, Terminated, Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Enrolling by invitation --> Terminated Enrolling by invitation --> Terminated
- | bapineuzumab (AAB-001) / Pfizer, J&J, Perrigo Company
Trial termination: AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Aug 23, 2012
P2, N=194, Terminated, Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Enrolling by invitation --> Terminated Active, not recruiting --> Terminated
- | bapineuzumab (AAB-001) / Pfizer, J&J, Perrigo Company
Enrollment change: RAPID: Retrieval of Patient Information After Discontinuation (clinicaltrials.gov) - Aug 23, 2012
P3b, N=169, Terminated, Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Active, not recruiting --> Terminated N=1300 --> 169
- |||||||||| New P3 trial: Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images (clinicaltrials.gov) - Aug 23, 2012
P3, N=276, Completed, Sponsor: GE Healthcare
- |||| solanezumab (LY2062430) / Eli Lilly
Biomarker, Trial completion: A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's (clinicaltrials.gov) - Aug 23, 2012
P2, N=55, Completed, Sponsor: Eli Lilly and Company
N=1300 --> 169 Active, not recruiting --> Completed
- Enrollment change: Screening and Interventions in an Acute Care Setting (clinicaltrials.gov) - Aug 22, 2012
P=N/A, N=187, Completed, Sponsor: University of Rochester
Active, not recruiting --> Completed N=1740 --> 187
- Enrollment change, Surgery: Cerebral Oximetry and Neurological Outcomes in Aortic Arch Surgery Patients (clinicaltrials.gov) - Aug 21, 2012
P3, N=25, Completed, Sponsor: University of Michigan
N=1740 --> 187 N=100 --> 25
- Trial completion, Surgery: Cerebral Oximetry and Neurological Outcomes in Aortic Arch Surgery Patients (clinicaltrials.gov) - Aug 21, 2012
P3, N=25, Completed, Sponsor: University of Michigan
N=100 --> 25 Recruiting --> Completed
- || rivastigmine transdermal / Generic mfg.
New P3 trial: RIVET: Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI (clinicaltrials.gov) - Aug 20, 2012
P3, N=256, Recruiting, Sponsor: Department of Veterans Affairs
- Enrollment closed, Metastases: Cognitive Impairment in Kidney Disease (clinicaltrials.gov) - Aug 20, 2012
P=N/A, N=190, Active, not recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- Enrollment change: Exploratory and Safety Study of [F-18]W372 (clinicaltrials.gov) - Aug 20, 2012
P0, N=24, Completed, Sponsor: Siemens Molecular Imaging
Enrolling by invitation --> Active, not recruiting N=20 --> 24
- | New P2 trial: Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease (clinicaltrials.gov) - Aug 19, 2012
P2, N=200, Suspended, Sponsor: Rock Creek Pharmaceuticals, Inc.
- Cerebrate (pinitol) / Humanetics
New P2 trial: A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease (clinicaltrials.gov) - Aug 16, 2012
P2, N=40, Recruiting, Sponsor: James J. Peters Veterans Affairs Medical Center
- || amphetamine/dextroamphetamine ER / Generic mfg.
New P2/3 trial: Adderall XR and Processing Speed in Multiple Sclerosis (MS) (clinicaltrials.gov) - Aug 15, 2012
P2/3, N=60, Not yet recruiting, Sponsor: London Health Sciences Centre
- || rivastigmine transdermal / Generic mfg.
Enrollment closed: Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine (clinicaltrials.gov) - Aug 13, 2012
P=N/A, N=300, Active, not recruiting, Sponsor: Dong-A University
N=20 --> 24 Not yet recruiting --> Active, not recruiting
- | New P2 trial: Transcranial Direct Current Stimulation in Patients With Disorders of Consciousness (clinicaltrials.gov) - Aug 13, 2012
P2, N=55, Completed, Sponsor: University Hospital of Liege
- New P1 trial: Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders (clinicaltrials.gov) - Aug 13, 2012
P1, N=4, Completed, Sponsor: University of Hawaii
- ||| New P2/3 trial: A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) (clinicaltrials.gov) - Aug 9, 2012
P2/3, N=48, Completed, Sponsor: Avid Radiopharmaceuticals
- Enrollment open: Measuring the Impact of Cognitive and Psychosocial Interventions in Persons With Mild Cognitive Impairment (clinicaltrials.gov) - Aug 8, 2012
P=N/A, N=162, Recruiting, Sponsor: Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Trial completion: International Validation of a Delirium Prediction Model for ICU Patients (clinicaltrials.gov) - Aug 8, 2012
P=N/A, N=2000, Completed, Sponsor: Radboud University
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- haloperidol / Generic mfg.
Trial completion: Evaluation of Delirium Prevention in Critically Ill Patients (clinicaltrials.gov) - Aug 8, 2012
P=N/A, N=650, Completed, Sponsor: Radboud University
Not yet recruiting --> Completed Recruiting --> Completed
- New P1 trial: 3ECog: Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly (clinicaltrials.gov) - Aug 8, 2012
P1, N=40, Recruiting, Sponsor: Duke-NUS Graduate Medical School
- amisulpride / Generic mfg.
Trial initiation date: Optimisation of Antipsychotic Drug Use in Older People (clinicaltrials.gov) - Aug 7, 2012
P4, N=120, Recruiting, Sponsor: Institute of Psychiatry, London
Recruiting --> Completed Initiation date: Nov 2011 --> May 2012
- amisulpride / Generic mfg.
Enrollment open: Optimisation of Antipsychotic Drug Use in Older People (clinicaltrials.gov) - Aug 7, 2012
P4, N=120, Recruiting, Sponsor: Institute of Psychiatry, London
Initiation date: Nov 2011 --> May 2012 Not yet recruiting --> Recruiting
- ||||| EVP-0962 / Forum Pharmaceuticals
New P2 trial: Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease (clinicaltrials.gov) - Aug 7, 2012
P2, N=52, Completed, Sponsor: EnVivo Pharmaceuticals, Inc.
- New P1 trial: A Study of Florbetapir (18F) in Japanese Healthy Volunteers (clinicaltrials.gov) - Aug 7, 2012
P1, N=7, Completed, Sponsor: Avid Radiopharmaceuticals
- modafinil / Generic mfg.
Enrollment change: Modafinil, Sleep, and Cognition in Cocaine Dependence (clinicaltrials.gov) - Aug 5, 2012
P=N/A, N=44, Completed, Sponsor: Yale University
Not yet recruiting --> Recruiting N=36 --> 44
- ||||||| Trial completion: Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline (clinicaltrials.gov) - Aug 5, 2012
P3, N=239, Completed, Sponsor: Avid Radiopharmaceuticals
N=36 --> 44 Active, not recruiting --> Completed
- modafinil / Generic mfg.
Trial completion: Modafinil, Sleep, and Cognition in Cocaine Dependence (clinicaltrials.gov) - Aug 5, 2012
P=N/A, N=44, Completed, Sponsor: Yale University
Active, not recruiting --> Completed Recruiting --> Completed
- Clinical: Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients (clinicaltrials.gov) - Aug 5, 2012
P=N/A, N=10, Recruiting, Sponsor: Patrick Moriarty, MD, FACP, FACC
- | citalopram / Generic mfg., venlafaxine / Generic mfg., donepezil / Generic mfg.
New P4 trial: DEP-CI: Combination Treatment Study for Memory Impairment and Depression (clinicaltrials.gov) - Aug 2, 2012
P4, N=80, Recruiting, Sponsor: New York State Psychiatric Institute
- olanzapine / Generic mfg., haloperidol / Generic mfg.
Trial termination: Haloperidol vs Olanzapine for the Management of ICU Delirium (clinicaltrials.gov) - Aug 1, 2012
P=N/A, N=200, Terminated, Sponsor: Richard Hall
Recruiting --> Completed Recruiting --> Terminated
- Trial completion: PRO-MH: 31P-MRS and Huntington Disease (clinicaltrials.gov) - Aug 1, 2012
P=N/A, N=30, Completed, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Recruiting --> Terminated Recruiting --> Completed
- Trial completion: Cognitive Assessment Battery (CAB) Beta Study (clinicaltrials.gov) - Aug 1, 2012
P=N/A, N=255, Completed, Sponsor: CHDI Foundation, Inc.
Recruiting --> Completed Recruiting --> Completed
- | gantenerumab (RG1450) / Roche, MorphoSys
New P1 trial: A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients (clinicaltrials.gov) - Aug 1, 2012
P1, N=28, Recruiting, Sponsor: Chugai Pharmaceutical
- Enrollment change, Surgery: HTN: Cognitive Dysfunction in Hypertensive Patients Having Spine Surgery (clinicaltrials.gov) - Jul 30, 2012
P=N/A, N=200, Recruiting, Sponsor: Columbia University
Recruiting --> Completed N=150 --> 200
- Enrollment change: Delirium in the Emergency Department: Novel Screening (clinicaltrials.gov) - Jul 25, 2012
P=N/A, N=406, Active, not recruiting, Sponsor: Vanderbilt University
N=150 --> 200 N=700 --> 406
- Clinical: DELINEATE: Delirium in the Emergency Department and Its Extension Into Hospitalization (clinicaltrials.gov) - Jul 25, 2012
P=N/A, N=250, Recruiting, Sponsor: Vanderbilt University
- Enrollment closed: Delirium in the Emergency Department: Novel Screening (clinicaltrials.gov) - Jul 25, 2012
P=N/A, N=406, Active, not recruiting, Sponsor: Vanderbilt University
N=700 --> 406 Recruiting --> Active, not recruiting
- Clinical: A Trial of Neurocognitive and Supportive Therapy Interventions for Individuals With Parkinson's Disease (clinicaltrials.gov) - Jul 18, 2012
P=N/A, N=30, Recruiting, Sponsor: Virginia Commonwealth University
- Trial completion: PHS II: Physicians' Health Study II (clinicaltrials.gov) - Jul 16, 2012
P=N/A, N=14641, Completed, Sponsor: Brigham and Women's Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| vanutide cridificar (PF-236806) / J&J, Perrigo Company, Pfizer
Enrollment change: Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease (clinicaltrials.gov) - Jul 16, 2012
P2, N=63, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed N=108 --> 63
- verubecestat (MK-8931) / Merck (MSD)
Trial completion: A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1]) (clinicaltrials.gov) - Jul 12, 2012
P1, N=32, Completed, Sponsor: Merck
N=108 --> 63 Active, not recruiting --> Completed